Clinical Trial Update: Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) [Phase 2, Phase 3]

View source ↗

Summary

A safety and efficacy study of eculizumab in Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) has completed (Phase 2/Phase 3) under s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shiga Toxin-producing Escherichia Coli Hemolytic-uremic Syndrome

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Shiga-like Toxin-producing Escherichia Coli | Phase 2, Phase 3 | Status: COMPLETED